AMBLE · RESEARCH PRODUCT INFORMATION

Product overview

The supplier identifies GLP-3 as LY3437943, also known as retatrutide, and describes research involving GLP-1, GIP and glucagon receptors. This mannitol-containing research vial is not represented as an approved weight-loss medicine, a substitute for a prescribed product or a product supplied by a clinical-trial sponsor.

Research use only — not for human consumption

For scientific research and development only. Intended for in-vitro laboratory work, not human or animal administration. Not for use as a medicine, diagnostic product, medical device, food, supplement or cosmetic. No dosing, injection or treatment instructions are provided.

Product specifications

Quantity	10mg
Unit	1 Vial
Physical Appearance	White powder
Salt form	Sodium
Supplier reference purity (not lot verification)	≥99%
Sequence	Y-Aib-QGTFTSDYSI-αMeLeu-LDK-Lys(19-carboxy- nonadecanoyl-γGlu-AEEA)-AQ-Aib-AFIEYLLEGGPSSGAPPPS-NH2
Source-reported molecular mass (units not stated)	4731.33
CAS NO.	2381089-83-2
Source-listed laboratory solvents	Bacteriostatic water
Excipient named by supplier	Mannitol; amount not specified in the source specification table

Product features

Source-listed pack: 10mg 1 Vial
Source-listed presentation: White powder
Excipient: Mannitol; amount not specified in the source specification table

These characteristics identify the supplier reference presentation. They are not independent testing or verification of the current Amble lot.

These are reference specifications reported on the corresponding Particle Peptides page, not independent analytical verification of an Amble lot. Confirm the received label, identity, formulation and batch documentation before laboratory use. Unlisted fields have not been invented.

Storage and handling

1. Research use and restrictions

Literature involving animals or clinical studies is background information only and does not authorize this product for those uses. Do not supply this material for human investigational use.

2. Peptides in transport

Follow the current product label and lot-specific transport documentation. A general supplier statement about transport stability is not a guarantee for every formulation, liquid, blend or Amble shipment. The source supplier lists shipping restrictions for: Canada, Croatia, Czech Republic, Iceland, Ireland, Luxemburg, Norway, Serbia, South Africa, Thailand, United States. This is the supplier’s published list, not a complete legal assessment or a replacement for Amble’s shipping policy.

3. Storage of lyophilized peptides

The supplier gives general guidance to protect lyophilized peptides from light and moisture. Storage temperature and expiry must follow the actual formulation and lot documentation. Do not treat a generic storage-duration table as validated shelf-life data for this Amble product.

4. Storage of reconstituted peptides

Solution stability depends on sequence, formulation, solvent and handling. Use product-specific stability documentation and laboratory procedures rather than assuming the same refrigerated life for all peptides. The supplier’s Ipamorelin stability discussion cannot be extrapolated to other products without supporting data.

5. Storage of peptide solutions

Avoid unnecessary freeze–thaw cycling and follow the documented conditions for the exact solution. This page does not establish a validated shelf life after preparation. The listed solvent information is a supplier reference, not a patient-use or injection protocol.

Overview of published research

The corresponding source page discusses the topics below. They describe areas of investigation, not proven customer benefits, treatment indications or evidence that this particular Amble batch has been tested.

GLP-1, GIP and glucagon-receptor signaling
Experimental metabolic regulation
Literature on body-weight and liver-related research

Interpretation depends on the study design, experimental material and model. The presence of a publication in a supplier bibliography is not an independent verification of the supplier’s interpretation or a guarantee of safety or effectiveness. No clinical doses or administration protocols are reproduced here.

Quality and documentation

Source attribution: the specifications and bibliography below refer to Particle Peptides. Amble branding does not turn the supplier’s studies or documents into Amble batch certifications.

View the corresponding supplier product page

Document links are retained as supplier references. Confirm lot matching, document authenticity and applicability before relying on them; this update does not independently verify those documents.

Bibliography listed by the supplier (7 entries)

Bibliographic entries are attributed to the source page. Individual citations have not all been independently validated; consult the original publications and distinguish primary studies from secondary reports.

„Retatrutide (LY3437943): A Novel Tri-agonist Peptide for Metabolic Disease Treatment”, 2025.
Alaa Abdrabou Abouelmagd et al., „Efficacy and safety of retatrutide, a novel GLP-1, GIP, and GCG receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials”, 2025.
Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple GCG, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234–1247.e9. doi: 10.1016/j.cmet.2022.07.013. [DOI] [PubMed]
Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30(7):2037–2048. doi: 10.1038/s41591-024-03018-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
Jastreboff AM, Kaplan LM, Frías JP, et al. Triple–hormone-receptor agonist retatrutide for obesity—a phase 2 trial. N Engl J Med. 2023;389(6):514–526. doi: 10.1056/NEJMoa2301972. [DOI] [PubMed]
Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and GCG receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023;402(10401):529–544. doi: 10.1016/S0140-6736(23)01053-X. [DOI] [PubMed]
Urva S, Coskun T, Loh MT, et al. LY3437943, a novel triple GIP, GLP-1, and GCG receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022;400(10366):1869–1881. doi: 10.1016/S0140-6736(22)02033-5. [DOI] [PubMed]

Product questions and answers

What is GLP-3 10mg with Mannitol (Retatrutide / LY3437943)?

What quantity is listed for GLP-3 (Retatrutide) 10mg?

The corresponding supplier reference lists 10mg 1 Vial. This applies to the stated presentation only; other strengths and quantities are not included.

Which identity or formulation details matter for GLP-3 (Retatrutide) 10mg?

The supplier provides 10 reference specification fields for this listing. Those fields and source documents are not an independent Amble batch certificate.

Does the linked documentation certify this Amble batch?

No Amble-lot certification is established by a supplier webpage or an unmatched COA. Confirm the laboratory report, exact batch number, identity and formulation before relying on the documentation.

What storage conditions are verified for GLP-3 (Retatrutide) 10mg?

Follow the actual lot label and product-specific safety and stability documentation. Generic storage tables and studies on another peptide do not establish this product’s shelf life.

Is GLP-3 (Retatrutide) 10mg intended for human use?

No. This is a research-use listing for in-vitro laboratory work, not human or animal administration. The page provides no dosing, injection or treatment instructions.

US online ordering information

Information for customers reviewing GLP-3 (Retatrutide) 10mg online from the United States.

This is a research-use listing, not a patient treatment or a finished medicine. Do not use it for human or animal administration. Review the exact formulation and lot-matched documentation, and confirm jurisdiction-specific eligibility before placing any order.

Use the live price and stock display on this page and review the final checkout total. Delivery, tax and return conditions depend on the product and destination; do not assume a delivery date or eligibility from this page alone.

For product or ordering questions, email hello@joinamblehealth.com. Read the Amble terms of service or visit your Amble account.

CAS 2381089-83-2

GLP-3 10mg with Mannitol (Retatrutide / LY3437943)